Skip to main content
Premium Trial:

Request an Annual Quote

Anne Kopf-Sill, Andrea Chow, Seth Cohen, H. Perry Fell, Robert Attiyeh, Dale Stringfellow


Caliper Technologies has laid off around 15 percent of its staff, or 65 individuals, including seven vice presidents (see complete story, page 8). The company has also added and promoted several individuals: Anne Kopf-Sill, vice president of microfluidics R&D, will become vice president of molecular diagnostics, and Andrea Chow will replace Kopf-Sill, as vice president of new products. Seth Cohen has been appointed the director of application scientists.

Seattle Genetics said that H. Perry Fell will step down as chief strategy officer and will become a consultant to the company. The move, which will take place at the end of the year, does not affect Fell’s position as chairman of the board.

Fell co-founded Seattle Genetics in 1997 and served as its CEO until November 2002, when he was appointed CSO. He has also served as chairman since April 2002. Fell is a member of the board of directors of International Therapeutics and an advisor to Nanostring Technologies, both of which are private biotechnology companies based in Seattle. He also serves on the board of the Washington Biotechnology and Biomedical Association.

Myriad Genetics has elected Robert Attiyeh to its board of directors.

Attiyeh was CFO and senior vice president of Amgen from 1994 to 1998. Prior to joining Amgen, he was a director of McKinsey and Company, a management-consulting firm, from 1967 to 1994, during which time he directed its Scandinavian office, helped establish the office in Osaka, Japan, and was active in Los Angeles.

Attiyeh was also a director of the Federal Reserve Board of San Francisco from 1987 through 1992, and chairman of the Federal Reserve Board’s Audit Review Committee from 1988 through 1992. He received his MBA from Harvard University in 1961 and his bachelor’s degree in electrical engineering from Cornell University.

Additionally, Myriad has named as its new chairman Dale Stringfellow, a director of Myriad Genetics since December 1991. Stringfellow was most recently president and CEO of Berlex, the US pharmaceutical division of Schering. Stringfellow earned his PhD in microbiology from the University of Utah.

Filed under

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.